Corrigendum: Clinicopathological and molecular characterization of astrocytoma

Xiaoyan Wu^1,2,3Wenfeng Peng^4,5Xu Zhang^2,3,6Tang Tao^2,6Ling Deng^3,7Yuxia Xu^2,6Xiaoyun Liu^2,6Fang Wang^2,6Wujian Peng^8,9Jianrong Huang^8,9*Xiaoni Zhong^10,11,12*

• ¹Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong Province, China
• ²State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, Guangdong, China
• ³Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China
• ⁴Shenzhen Second People's Hospital, Shenzhen, Guangdong Province, China
• ⁵Department of Pathology, Shenzhen University 1st Affiliated Hospital,Shenzhen University School of Medicine, Shenzhen, China
• ⁶Department of Molecular Diagnostics, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China
• ⁷Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, Guangdong, China
• ⁸Department of Nephrology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province, China
• ⁹Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China
• ¹⁰Department of Pathology, Shenzhen People's Hospital, Jinan University, Shenzhen, China
• ¹¹The Second Affiliated Hospital of Jinan University, Shenzhen, China
• ¹²First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China

"[Astrocytoma is a rare tumour of the central nervous system that often manifests with non-speciffc clinical symptoms and lacks distinct histological features. There is a pressing need for further understanding of the clinicopathological and molecular characteristics of astrocytoma.]"The corrected sentence appears below: "[Astroblastoma is a rare tumour of the central nervous system that often manifests with nonspecifc clinical symptoms and lacks distinct histological features. There is a pressing need for further understanding of the clinicopathological and molecular characteristics of astroblastoma.]"In the published article, there was an error. [misspelling].A correction has been made to [Discussion]. This sentence previously stated: "[Our study unveiled the distinctive clinicopathological and molecular mutational characteristics of astrocytoma, while also identifying rare mutated genes. Our study unveiled the distinctive clinicopathological and molecular mutational characteristics of astrocytoma, while also identifying rare mutated genes.]"PAGE \* Arabic \* MERGEFORMAT 3The corrected sentence appears below: "[Our study unveiled the distinctive clinicopathological and molecular mutational characteristics of astroblastoma, while also identifying rare mutated genes. Additionally, the detection of MN1 or EWSR1 gene fusion through FISH or next-generation sequencing can provide valuable insights into the molecular mechanisms and aid in the diferential diagnosis of astroblastoma.]"In the published article, there was an error. The corrected sentence appears below: "[IHC characteristics of astroblastoma cases.]" Astroblastoma is a rare and distinct CNS tumor that has been clearly established as an independent entity in the WHO classification system. Its unique histological and molecular characteristics set it apart from astrocytoma. The following content provides a detailed overview of the classification of astroblastoma in the WHO system.The first edition of the WHO classification, published in 1979 [1], categorized nervous system tumors into ten major categories. In the WHO CNS 1 classification system, these categories include neoplasms of neuroepithelial tissue, tumors of nerve sheath, tumors of meninges and related tissues, primary malignant lymphomas, tumors derived from vascular tissue, germ cell tumors, other morphological tumors and tumor-like lesions, vascular malformations, anterior pituitary tumors, and local tumor invasions. Among these, tumors of neuroepithelial tissue are further subdivided into six subcategories: astrocytic tumors, which include pilocytic astrocytoma, astrocytoma, subependymal giant cell astrocytoma, astroblastoma, and anaplastic astrocytomaas shown in Figure 1. The World Health Organization (WHO) announced the second version of the Central Nervous System (CNS) classification system in 1993 [2]. This grading system primarily relies on histological characteristics, as illustrated in Figure 2. The World Health Organization (WHO) released the WHO Classification of Tumors of the Central Nervous System (CNS) 3rd edition at the beginning of 2000 [3]. This edition categorizes nervous system tumors into seven major groups: neoplasms of neuroepithelial tissue, peripheral nerve tumors, tumors derived from the meninges, lymphomas and tumors of the hematopoietic system, germ cell tumors, tumors of the sellar region, and metastatic tumors. Refer to Figure 3 for further illustration.PAGE \* Arabic \* MERGEFORMAT 3PAGE \* Arabic \* MERGEFORMAT 3 The World Health Organization (WHO) Central Nervous System Classification, fourth edition, was published in 2007 [4]. This edition presents the classification of nervous system tumors, as illustrated in Figure 4. The 2016 World Health Organization (WHO) Central Nervous System Classification (Revised Version 4) [5], as shown in Figure 5. methods, as well as newly adopted methylation analysis and copy number variation. These integrations provide a robust foundation for comprehensive hierarchical analysis. Furthermore, the new classification offers insights into key gene alterations, molecular changes, and signaling pathway modifications associated with several common tumors. Building on this foundation, a new hierarchical diagnostic recommendation format has been established. The integrated diagnostic approach, which combines histological diagnosis, WHO grading, and molecular testing results, represents the optimal strategy. See Figure 6. fusion. Histologically, cubic or columnar tumor cells are observed growing in a pseudopapillary or perivascular manner, with a non-nuclear area surrounding the blood vessels. The blood vessels and tumor cells exhibit transparency in their vicinity. Molecular pathological examinations can reveal MN1 variation, most commonly represented as MN1-BEND2 fusion. Consequently, the astroblastoma discussed in this research is distinct from astrocytoma. The mention of astrocytoma in the text is entirely a clerical error, which we hope can be rectified. Thank you!